Radioactive drug takes on brain cancer in early trial
NCT ID NCT05450744
First seen Jan 24, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This early-phase trial is testing a radioactive drug called 131I-TLX101, given alongside standard care, for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study involves 12 participants and aims to find the safest dose and check for side effects. It is not yet known if the drug helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gold Coast University Hospital
RECRUITINGGold Coast, Queensland, 4215, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut für Nuklearmedizin und Endokrinologie
RECRUITINGLinz, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Olivia Newton John Cancer Research Institute/Austin Health
RECRUITINGMelbourne, Victoria, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal North Shore Hospital
RECRUITINGSydney, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UNMC Utrecht
RECRUITINGUtrecht, 3051, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
131I-TLX101 (a radioactive drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for glioblastoma, a tough brain cancer.
What could go wrong
This is a very early phase 1 trial with only 12 people, focused on safety and dosing. It may not show benefit, and there are risks like side effects from radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.